Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01356420 · ClinicalTrials.gov registry record · NA
Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome
A NA study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT01356420 is a NA study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 21 participants.
The verdict
NCT01356420, a NA study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about Smith-Lemli-Opitz Syndrome (SLOS). SLOS is an inherited condition that is caused by the body not making an enzyme as it should. The body needs the enzyme to help make cholesterol. SLOS can cause many health problems including slow growth and development, eating disorders, sleep disorders, behavior disorders, and eye diseases. Severe SLOS leads to birth defects and mental retardation and in many cases early death. The investigators plan to measure cholesterol and other sterol levels, perform clinical observations, whole body testing and imaging (brain MRIs), to learn more about the disease and its progression, differences in the clinical features among individuals with SLOS, and look at the effect of cholesterol supplementation in this condition. The study is an interventional study to characterize disease progression and correlations between clinical, biochemical and physiological features of the disease. The main hypothesis is that dietary cholesterol supplementation does not improve features of SLOS related to the brain (e.g. IQ, behavior).
Interventions
- DIETARY_SUPPLEMENT Cholesterol supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01356420
The ClinicalTrials.gov registry entry for NCT01356420 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cholesterol supplementation is the first listed.
NCT01356420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01356420 about?
NCT01356420 is a clinical study titled "Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome". The purpose of this study is to learn about Smith-Lemli-Opitz Syndrome (SLOS). SLOS is an inherited condition that is caused by the body not making an enzyme as it should. The body needs the enzyme to help make cholesterol. SLOS can cause many health problems including slow growth and development, e...
What is the current status of trial NCT01356420?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2011-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01356420?
The interventions under investigation include: Cholesterol supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01356420?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.